Boehringer Ingelheim International Gmbh

Amgen Inc.

Patricia Amouzegh

Doris Riether

Renee M Zindell

Alessandra Bartolozzi

Monika Ermann

Innocent Mushi

Nigel James Blumire

Eugene R Hickey

David S Thomson

Lifen Wu

Achim Sauer

Angela Kay Berry

Stephen East

Someina Khor

Markus Ostermeier

Xiaotian Zhu

Joseph J Nunes

Heather Tye

Matthias Treu

Cristina Lecci

Stephan Karl Zahn

Chiara Ghiron

Robert John Scott

Stephen Peter East

Eugene Richard Hickey

Eoin Christopher Power

David N Johnson

David Smith Thomson

The present invention encompasses compounds of general formula (I) wherein the groups Rto R, A, L, B, m and p are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

Benzylic oxindole pyrimidines

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Compounds which selectively modulate the CB2 receptor

Therapeutic uses of compounds which selectively modulate the CB2 receptor

are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.

Substituted heterocyclic compounds and methods of use

Growing community of inventors

Didcot, United Kingdom

Patricia Amouzegh